Although there is a modest change in mean DAS28 level at the end of 6 months, yet the significant reduction supports the concept that pathways targeted by statins offer therapeutic opportunity in RA.[ 1 ] Many data indicate effects for statins in innate immune response, manifest on endothelial activation,[ 2 ] macrophage, natural killer cells, and neutrophil effector function.[ 5 ] Similar effects on acquired immune responses via suppression of antigen presentation[ 6 ] and T-cell polarization have been shown in vitro and in vivo .[ 7 , 8 ] In this study, mean level of CRP showed a decreasing trend after 6 months of follow-up in the patients of group 1 (with adjunct statin) than group 2.
1
—
—